Zacks: Analysts Anticipate Cellectis S.A. (NASDAQ:CLLS) to Announce -$0.55 Earnings Per Share

Analysts expect that Cellectis S.A. (NASDAQ:CLLSGet Rating) will report earnings of ($0.55) per share for the current quarter, Zacks reports. Two analysts have made estimates for Cellectis’ earnings, with the highest EPS estimate coming in at ($0.20) and the lowest estimate coming in at ($0.85). Cellectis reported earnings per share of ($0.88) in the same quarter last year, which would indicate a positive year over year growth rate of 37.5%. The company is expected to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Cellectis will report full year earnings of ($2.31) per share for the current fiscal year, with EPS estimates ranging from ($3.25) to ($1.09). For the next fiscal year, analysts forecast that the company will report earnings of ($1.19) per share, with EPS estimates ranging from ($1.68) to ($0.85). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover Cellectis.

Cellectis (NASDAQ:CLLSGet Rating) last released its quarterly earnings data on Thursday, March 3rd. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.50. The business had revenue of $13.66 million during the quarter, compared to analysts’ expectations of $12.30 million. Cellectis had a negative return on equity of 53.48% and a negative net margin of 312.64%. During the same period in the prior year, the firm posted ($0.95) EPS.

Several analysts have recently weighed in on the company. Zacks Investment Research downgraded Cellectis from a “buy” rating to a “hold” rating in a report on Monday. Robert W. Baird raised Cellectis from a “neutral” rating to an “outperform” rating and set a $10.00 target price for the company in a report on Wednesday, May 18th. They noted that the move was a valuation call. The Goldman Sachs Group reduced their price objective on Cellectis from $3.00 to $2.00 and set a “sell” rating for the company in a research note on Tuesday. Barclays reduced their price objective on Cellectis from $9.00 to $7.00 in a research note on Friday, May 13th. Finally, StockNews.com raised Cellectis from a “sell” rating to a “hold” rating in a research note on Friday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $15.25.

Shares of Cellectis stock traded up $0.21 on Friday, hitting $3.98. The stock had a trading volume of 87,769 shares, compared to its average volume of 249,591. Cellectis has a 52-week low of $2.85 and a 52-week high of $16.53. The company has a current ratio of 3.73, a quick ratio of 3.73 and a debt-to-equity ratio of 0.09. The stock has a market cap of $181.13 million, a price-to-earnings ratio of -1.35 and a beta of 2.24. The company’s 50 day moving average price is $3.94 and its 200 day moving average price is $5.89.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in Cellectis by 60.0% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 31,607 shares of the biotechnology company’s stock worth $277,000 after purchasing an additional 11,858 shares during the period. OLD Mission Capital LLC acquired a new position in Cellectis during the 3rd quarter worth approximately $253,000. Jane Street Group LLC acquired a new position in Cellectis during the 3rd quarter worth approximately $2,212,000. Deutsche Bank AG acquired a new position in Cellectis during the 3rd quarter worth approximately $42,000. Finally, Millennium Management LLC increased its position in Cellectis by 180.9% during the 3rd quarter. Millennium Management LLC now owns 186,140 shares of the biotechnology company’s stock worth $2,347,000 after purchasing an additional 119,872 shares during the period. Institutional investors own 40.55% of the company’s stock.

About Cellectis (Get Rating)

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia.

Featured Stories

Get a free copy of the Zacks research report on Cellectis (CLLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.